$EDIT ACCE Score Jumps 18 Points to 49 on Momentum Surge
Editas Medicine's ACCE composite score rose from 31 to 49. Here's what's driving the move and what the subscore breakdown tells us about $EDIT right now.
Editas Medicine's ($EDIT) ACCE composite score moved from 31 to 49, a delta of +18 points. That's a meaningful single-step jump for a stock in the healthcare space, and the subscore breakdown tells a clear story about where the strength is coming from — and where the risks still sit.
The four subscores as of August 11, 2026:
Momentum: 90/100
Growth: 64/100
Quality: 27/100
Value: 13/100
A composite score move of +18 points almost always reflects a sharp improvement in one or two subscores rather than a broad lift across all four. Given that Momentum sits at 90 — the highest reading in the breakdown — the most likely driver of the score jump is a surge in price and volume momentum. $EDIT is up 35.0% over the past year, and at $2.97 the stock has been moving. Analyst consensus sits at a $6.00 target, implying significant upside from the current price, and that gap can itself attract momentum-oriented attention.
The Growth score of 64 also contributes positively. Revenue grew 232.3% year-over-year, which is a striking top-line acceleration for a clinical-stage biotech. That kind of revenue growth, even from a small base, tends to lift the Growth subscore materially. $EDIT also posted a narrow beat in its most recent quarter (Q3 FY2026), coming in +0.5% above estimates.
Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.
What it means
The score improvement is real, but the breakdown demands context. Quality at 27 and Value at 13 are both low readings, and the underlying financials explain why. ROE stands at -118.8%, net margin at -157.3%, and FCF yield at -37.5%. Earnings quality is flagged as mixed. These are not unusual numbers for a pre-profitability gene-editing company burning cash to fund its pipeline, but they do cap how high the composite score can realistically go until the business model matures.
The Value score of 13 reflects the difficulty of applying traditional valuation metrics to a company with no earnings and negative cash flow. Forward and trailing P/E ratios are not applicable here.
What the score move signals is that $EDIT has shifted from a stock with weak momentum and modest growth signals to one where the market is paying attention. A Momentum score of 90 is not something that appears quietly. It reflects sustained price action and relative strength versus peers.
For a fuller picture of current pricing and model fair-value estimates, see the live $EDIT page at acceinvestments.com/stocks/EDIT.
ACCE scores thousands of stocks across valuation models matched to each company, with fair value, conviction and the full thesis on every name. Start free, no card required.
